alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 351–375 of 851 studies with an author at University College London (GB) (page 15 of 35) · 27,780 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 13,259 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Journal of neurology, neurosurgery, and psychiatry 2013-06-18

(1) outlook in PD is heterogeneous, with most dying or developing dementia or postural instability by 10 years from diagnosis, but a quarter still doing well, with preserved mobility and intact cognition; (2) death is not directly related to PD in the majority; (3) baseline clinical and genetic variables are predictive of outcome and may be helpful in selecting patients for clinical trials. 1 key finding →

Participants: 142 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

A chronological map of 308 physical and mental health conditions from 4 million individuals in the English National Health Service

✓ Peer-reviewed alzhub usefulness score 59 out of 100. The Lancet. Digital health 2019-05-20

We used records of 2 784 138 patients for the calculation of cumulative incidence and of 3 872 451 patients for the calculation of period prevalence and median age at diagnosis of these conditions. 5 key findings →

Participants: 138 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Volumetric MRI and cognitive measures in Alzheimer disease : comparison of markers of progression

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Journal of neurology 2008-02-18

Rates of brain atrophy and/or ventricular enlargement were correlated with declining performance on cognitive scales. 2 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

The pattern of atrophy in familial Alzheimer disease: volumetric MRI results from the DIAN study

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Neurology 2013-09-18

Atrophy in FAD is observed early, both in areas commonly associated with sporadic Alzheimer disease and also in the putamen and thalamus, 2 regions associated with early amyloid deposition in FAD mutation carriers. 4 key findings →

Design: cross-sectional Participants: 192 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Staging tau pathology with tau PET in Alzheimer's disease: a longitudinal study

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Translational psychiatry 2021-09-18

A biological research framework to define Alzheimer' disease with dichotomized biomarker measurement was proposed by National Institute on Aging-Alzheimer's Association (NIA-AA). 3 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

A systematic review of the prevalence and covariates of anxiety in caregivers of people with dementia

✓ Peer-reviewed alzhub usefulness score 59 out of 100. International psychogeriatrics 2006-09-28

Coping style may be more associated with anxiety than depression while other covariates (burden and poor physical health) are similar to those for caregiver depression. 5 key findings →

Design: systematic review Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Brain : a journal of neurology 2016-07-07

The aim of this study was to assess the agreement between data on cerebral amyloidosis, derived using Pittsburgh compound B positron emission tomography and (i) multi-laboratory INNOTEST enzyme linked immunosorbent assay derived cerebrospinal fluid concentrations of amyloid-β42; (ii) centrally measured cerebrospinal fluid amyloid-β42 using a Meso Scale Discovery enzyme linked immunosorbent assay; and (iii) cerebrospinal fluid amyloid-β42 centrally measured using an antibody-independent mass spectrometry-based reference method. 3 key findings →

Participants: 243 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study

✓ Peer-reviewed alzhub usefulness score 59 out of 100. The Lancet. Neurology 2006-10-01

Mutation carriers had significantly increased hippocampal and whole-brain atrophy rates compared with controls and these differences increased with time. 2 key findings →

Design: cross-sectional Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Tau PET correlates with different Alzheimer's disease-related features compared to CSF and plasma p-tau biomarkers

✓ Peer-reviewed alzhub usefulness score 59 out of 100. EMBO molecular medicine 2021-07-13

PET, CSF and plasma biomarkers of tau pathology may be differentially associated with Alzheimer's disease (AD)-related demographic, cognitive, genetic and neuroimaging markers. 3 key findings →

Participants: 400 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Xenografted human microglia display diverse transcriptomic states in response to Alzheimer's disease-related amyloid-β pathology

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Nature neuroscience 2024-03-27

Microglia are central players in Alzheimer's disease pathology but analyzing microglial states in human brain samples is challenging due to genetic diversity, postmortem delay and admixture of pathologies. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Journal of hepatology 2024-12-19

& aims The combination of atezolizumab and bevacizumab (atezo+bev) is the current standard of care for advanced hepatocellular carcinoma (HCC), providing a median overall survival (OS) of 19.2 months. 4 key findings →

Participants: 317 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Association of CSF GAP-43 With the Rate of Cognitive Decline and Progression to Dementia in Amyloid-Positive Individuals

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Neurology 2022-10-03

In this retrospective study, GAP-43 was measured in participants from the AD Neuroimaging Initiative (ADNI) cohort using an in-house ELISA method, and levels were compared between groups, both cross-sectionally and longitudinally. 4 key findings →

Participants: 786 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Alzheimer's research & therapy 2018-07-28

A growing body of evidence suggests that the plasma concentration of the neurofilament light chain (NfL) might be considered a plasma biomarker for the screening of neurodegeneration in Alzheimer's disease (AD). 4 key findings →

Participants: 25 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The relationship between sleep duration, cognition and dementia: a Mendelian randomization study

✓ Peer-reviewed alzhub usefulness score 59 out of 100. International journal of epidemiology 2019-06-01

Linear MR suggested that each additional hour/day of sleep was associated with 1% [95% confidence interval (CI) = 0-2%; P = 0.008] slower reaction time and 3% more errors in visual-memory test (95% CI = 0-6%; P = 0.05). 4 key findings →

Participants: 395 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Parkinson's disease determinants, prediction and gene-environment interactions in the UK Biobank

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Journal of neurology, neurosurgery, and psychiatry 2020-10-01

We identified individuals with an incident diagnosis of PD (n=1276) and controls (n=500 406) in UK Biobank. 4 key findings →

Participants: 1,276 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Association of Type 2 Diabetes, According to the Number of Risk Factors Within Target Range, With Structural Brain Abnormalities, Cognitive Performance, and Risk of Dementia

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Diabetes care 2021-09-29

Type 2 diabetes is associated with increased risks of cognitive dysfunction and brain abnormalities. 4 key findings →

Participants: 10,663 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Annals of clinical and translational neurology 2015-11-20

Widespread implementation of cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD) in clinical settings requires improved accuracy for diagnosis of prodromal disease and for distinguishing AD from non-AD dementias. 4 key findings →

Participants: 338 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Subjective cognitive decline predicts longitudinal neuropsychological test performance in an unsupervised online setting in the Brain Health Registry

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Alzheimer s Research & Therapy 2025-01-07

(n = 16,683) had an average age of 69.07 ± 7.34, 72.04% were female, and had an average of 16.66 ± 2.26 years of education. 5 key findings →

Design: longitudinal study Participants: 16,683 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Movement Disorders 2017-05-03

Here, we present new criteria aimed to optimize early, sensitive, and specific clinical diagnosis of PSP on the basis of currently available evidence. © 2017 International Parkinson and Movement Disorder Society.

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed